Intuitive Surgical, Inc. (NASDAQ:ISRG) Holdings Raised by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. lifted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,132 shares of the medical equipment provider’s stock after purchasing an additional 801 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Intuitive Surgical were worth $4,768,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ISRG. Vanguard Group Inc. raised its holdings in Intuitive Surgical by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock worth $8,730,184,000 after buying an additional 196,316 shares during the period. Jennison Associates LLC grew its stake in Intuitive Surgical by 6.4% during the 3rd quarter. Jennison Associates LLC now owns 4,585,190 shares of the medical equipment provider’s stock valued at $1,340,205,000 after acquiring an additional 274,692 shares in the last quarter. Invesco Ltd. grew its stake in Intuitive Surgical by 6.6% during the 3rd quarter. Invesco Ltd. now owns 3,750,490 shares of the medical equipment provider’s stock valued at $1,096,231,000 after acquiring an additional 232,205 shares in the last quarter. Northern Trust Corp grew its stake in Intuitive Surgical by 3.4% during the 3rd quarter. Northern Trust Corp now owns 3,514,421 shares of the medical equipment provider’s stock valued at $1,027,230,000 after acquiring an additional 115,059 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Intuitive Surgical by 0.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,030,415 shares of the medical equipment provider’s stock valued at $593,470,000 after acquiring an additional 17,477 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Insider Activity at Intuitive Surgical

In related news, EVP Myriam Curet sold 5,318 shares of the company’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total value of $1,971,169.88. Following the completion of the transaction, the executive vice president now directly owns 298 shares in the company, valued at $110,456.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Intuitive Surgical news, EVP Myriam Curet sold 5,318 shares of the company’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total value of $1,971,169.88. Following the sale, the executive vice president now directly owns 298 shares in the company, valued at $110,456.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the sale, the director now owns 25,319 shares in the company, valued at $9,385,753.30. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 249,418 shares of company stock worth $96,300,959. 0.90% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on ISRG. Wells Fargo & Company lifted their target price on Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research note on Friday, January 19th. Stifel Nicolaus upped their target price on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Royal Bank of Canada upped their target price on Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 24th. Robert W. Baird decreased their target price on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research report on Friday, April 19th. Finally, Raymond James upped their target price on Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $396.17.

Intuitive Surgical Stock Up 0.6 %

Shares of ISRG stock opened at $375.33 on Friday. The stock has a 50 day moving average of $386.19 and a 200-day moving average of $345.95. The firm has a market cap of $133.13 billion, a PE ratio of 67.75, a price-to-earnings-growth ratio of 4.82 and a beta of 1.36. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The business had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. Intuitive Surgical’s revenue was up 11.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.00 earnings per share. As a group, equities analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.